Christian Jakobsen

Christian Jakobsen

Auto-generated profile, based on publicly available information

Christian Jakobsen

Department of Pediatrics Hvidovre Hospital, Copenhagen University Hospital Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2014 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
CJC. Jakobsen
C. Jakobsen
Isabelle CleynenIsabelle Cleynen
Isabelle Cleynen
PAP.S. Andersen
P.S. Andersen
SVSeverine Vermeire
Severine Vermeire
PMP. Munkholm
P. Munkholm
VWV. Wewer
V. Wewer
To investigate the association between known inflammatory bowel disease (IBD)-associated genetic variants and development of paediatric IBD, and specific clinical sub-phenotypes. In this case-control study we included IBD patients <18 years of age at diagnosis from the Danish National Patient Registry and healthy children <18 years of age were randomly selected from the Danish Central Office of Civil Registration. The latter had filled out a questionnaire regarding health status, and DNA was obtained from blood samples and the buccal mucosa. Patient files were retrieved and clinical information was extracted. DNA was obtained from Guthrie cards from the Danish National Neonatal Screening Biobank (PKU-biobanken) at Statens Serum Institut and from blood samples. A total of 588 IBD patients (244 Crohn's disease (CD), 318 ulcerative colitis (UC) and 26 IBD-unclassified (IBDU)) and 543 healthy controls were included. We found an association between CD and rs22411880 (ATG16L1, odds ratio (OR)=1.7 [1.1-1.7], p=0.003), rs5743289 (NOD2, OR=1.4 [1.1-1.9], p=0.009) and the paediatric specific rs1250550 (ZMIZ1, OR=0.7 [0.5-0.9], p=0.01). None of the investigated 41 SNPs were associated with disease localisation, medical treatment or surgery after correcting for multiple analyses. We found an association between CD and three previously published genetic variants and replicated the association with the paediatric specific ZMIZ1 gene. No Bonferroni corrected significant genotype-phenotype associations were found. For future studies aimed at finding predictors for disease course in (paediatric) IBD, it will be worthwhile to include a combination of genetic, clinical and serological markers.

11 May 2022 in GastroHep
Verified
Journal Article
Open access
PDF file
GNGiaan Ninh
Giaan Ninh
TKThomas Kallemose
Thomas Kallemose
VWVibeke Wewer
Vibeke Wewer
CJChristian Jakobsen
Christian Jakobsen
Background and Aims. In very early-onset IBD patients (VEO-IBD), studies have shown an incidence ranging from 0.4 to 2.1/100,000, extensive disease location, and a corresponding difficult and debatable treatment. We therefore aimed to investigate the incidence and medical and surgical treatment of VEO-IBD in a well-defined Danish population-based cohort. Methods. All VEO-IBD patients, defined as an IBD diagnosis before 6 years of age, were included from the Capital Region and the Zealand Region in 2015-2020. Demographic and clinical data including medical and surgical treatment were systematically extracted from the patient files. Results. Forty VEO-IBD patients were identified, 11 diagnosed with CD, 23 UC, and 6 IBD-U. The incidence rate of VEO-IBD was 2.0/100,000 (95 CI 0.8-5.9). All VEO-IBD patients except one had extensive colonic involvement or pancolitis. A total of 34 (85.0) and 23 (57.5) of the VEO-IBD patients received immunomodulators and/or biologicals, respectively. The cumulative risks of receiving immunomodulators and/or biologicals after 1/3/5 years was 55.3/86.8/90.1 and 36.8/45.9/57.0, respectively. During follow-up, six VEO-IBD patients (15.0) were treated with vedolizumabalthough off-label for this age groupas second-line biological therapy. Four patients (17.4) with UC had a colectomy. Two colectomised patients were treated with vedolizumab. Conclusion. Our population-based study showed an incidence of VEO-IBD comparable with the incidence in other countries. The population were treated intensively with immunomodulators and biologicalsincluding off-label vedolizumaband compared to other studies had the same risk of undergoing IBD-related surgeries.

22 May 2025 in JPGN Reports
Verified
Journal Article
Open access
CRChristine Rungoe
Christine Rungoe
SSStefan Stender
Stefan Stender
NDNawar Dalila
Nawar Dalila
EBEmil D. Bartels
Emil D. Bartels
CJChristian Jakobsen
Christian Jakobsen
We present a case of a young female patient with persistent and severe fat‐soluble vitamin deficiency since infancy. Despite extensive investigations during childhood, the underlying cause remained elusive. The patient was generally asymptomatic while receiving continuous vitamin subsidy. Exome sequencing performed at age 18 revealed a homozygous missense variant (Pro65Leu) in the gene SLC10A2, which encodes a bile acid transporter in the ileum. A bile retention scan showed severe bile acid malabsorption, with only 1.6% of radioactively labeled bile acids retained 7 days after intake. Treatment with a bile acid sequestrant was attempted but discontinued due to side effects and no significant effect on intestinal vitamin uptake. This case highlights the importance of early genetic testing in patients with unexplained fat‐soluble vitamin deficiency. It also emphasizes the need for further research to elucidate the clinical spectrum and management of primary bile acid malabsorption due to SLC10A2 deficiency.

5 November 2026 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
LSLuca Scarallo
Luca Scarallo
PLPaolo Lionetti
Paolo Lionetti
JKJaroslaw Kierkus
Jaroslaw Kierkus
LCLauren Collen
Lauren Collen
VRVictoria Riedl
Victoria Riedl
YWYael Weintraub
Yael Weintraub
Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.